CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 441 enrolled
Drug / intervention
biphasic insulin aspart 30 +2 moredrug
Likely dose
metformin 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00627445
NCT00627445Phase 3Completed
CompareCT.gov

Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Mar 3, 2008·Updated Oct 22, 2014

In Brief

A Phase 3 clinical trial evaluating biphasic insulin aspart 30, metformin, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 441 participants across 1 site.

Detailed Summary

This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 3, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.3 years ago

Interventions

biphasic insulin aspart 30drug

Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner

metformindrug

Tablets, 500 - 2000 mg, once, twice or three times daily

biphasic insulin aspart 50drug

Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch